BMS Ends Cellares Partnership Over Production Failures, Triggering ~100 Layoffs
NewsData.io · United States · Aug 26, 2026
Bristol Myers Squibb has terminated its $380 million capacity agreement with cell therapy manufacturer Cellares after determining the company's Cell Shuttle system could not meet requirements for commercial production of CAR-T therapy Breyanzi. Cellares will lay off approximately 100 employees on October 20, per a California WARN Act filing, affecting roles across engineering, marketing, recruitment, and software. The cuts come just 10 months after Cellares raised $257 million to scale toward commercial production. The layoffs signal continued volatility in the CDMO/cell therapy manufacturing sector, with ripple effects for specialized biotech talent demand.
Related stories
The Walt Disney Company is laying off approximately 300 employees in its latest restructuring round, primarily affecting technology and human…
A federal judge approved a five-year settlement clearing the way for Paramount's $111 billion acquisition of Warner Bros…
The University of Utah's Academic Senate addressed two major workforce changes: a projected 5–15% reduction in staff positions, with final decisions…
Disney has conducted three rounds of layoffs in 2026, affecting marketing, Pixar (at least 116–150 employees), ABC News, and ESPN, with a broader…